{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:09:47Z","timestamp":1791328187837,"version":"4.3.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"7","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.autrev.2013.02.002","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T09:04:07Z","timestamp":1362474247000},"page":"774-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies"],"prefix":"10.1016","volume":"12","author":[{"given":"D.","family":"Saadoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bienvenu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Trad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0005","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0002-9394(01)00830-3","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"131","author":"Jabs","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.autrev.2013.02.002_bb0010","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s00417-010-1485-8","article-title":"Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease","volume":"248","author":"Heiligenhaus","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.autrev.2013.02.002_bb0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/kel041","article-title":"Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra)","volume":"45","author":"Vounotrypidis","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","article-title":"Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study","volume":"71","author":"Gul","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab \u2014 a novel therapy for non-organ-specific autoimmune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.autrev.2012.07.012","article-title":"Cogan's syndrome: an autoimmune inner ear disease","volume":"12","author":"Greco","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0045","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/ken489","article-title":"Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis","volume":"48","author":"Yoshimura","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2013.02.002_bb0050","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1167\/iovs.10-6272","article-title":"Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis","volume":"52","author":"Haruta","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0055","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.autrev.2013.02.002_bb0060","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/s10165-011-0497-5","article-title":"A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab","volume":"22","author":"Hirano","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2013.02.002_bb0065","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3899\/jrheum.120010","article-title":"Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?","volume":"39","author":"Tappeiner","year":"2012","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2012.07.027","article-title":"Biologic drugs in autoinflammatory syndromes","volume":"12","author":"Caorsi","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2013.02.002_bb0075","first-page":"2462","article-title":"Quantitative assessment of the integrity of the blood\u2013retinal barrier in mice","volume":"43","author":"Derevjanik","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.autrev.2013.02.002_bb0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.autrev.2013.02.002_bb0085","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2013.02.002_bb0090","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.autrev.2013.02.002_bb0095","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Behcet uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.autrev.2013.02.002_bb0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0115","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":"Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-2008-1027361","article-title":"Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital","volume":"225","author":"Petropoulos","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Diaz-Llopis","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.autrev.2013.02.002_bb0130","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.autrev.2013.02.002_bb0135","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.ophtha.2012.02.018","article-title":"Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients","volume":"119","author":"Diaz-Llopis","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2013.02.002_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2012-302292","article-title":"Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial","author":"Suhler","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.2008.150961","article-title":"Infliximab for the treatment of refractory scleritis","volume":"94","author":"Doctor","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","article-title":"Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry","volume":"40","author":"Zannin","year":"2013","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0155","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.20404","article-title":"Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab","volume":"63","author":"Simonini","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2013.02.002_bb0160","article-title":"Infliximab treatment of patients with birdshot retinochoroidopathy","author":"Artornsombudh","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2013.02.002_bb0165","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S0012-3692(15)50471-6","article-title":"Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial","volume":"128","author":"Baughman","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semarthrit.2011.12.006","article-title":"Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review","volume":"42","author":"Maneiro","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0175","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0180","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases","volume":"41","author":"Wendling","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2013.02.002_bb0185","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","article-title":"Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis","volume":"51","author":"Baraliakos","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.02.002_bb0190","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","article-title":"Type I interferons in Sjogren's syndrome","volume":"12","author":"Yao","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3350\/kjhep.2011.17.1.61","article-title":"Vogt\u2013Koyanagi\u2013Harada disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C","volume":"17","author":"Lim","year":"2011","journal-title":"Korean J Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0200","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","article-title":"Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon","volume":"278","author":"Tsambaos","year":"1986","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0205","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2013.02.002_bb0210","article-title":"Light on the Horizont: biologicals in Behcet uveitis","author":"Hazirolan","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.autrev.2013.02.002_bb0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000336324","article-title":"Interferon-alpha therapy in noninfectious uveitis","volume":"51","author":"Deuter","year":"2012","journal-title":"Dev Ophthalmol"},{"issue":"10","key":"10.1016\/j.autrev.2013.02.002_bb0220","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":"Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2013.02.002_bb0225","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","article-title":"Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study","volume":"26","author":"Deuter","year":"2006","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.autrev.2013.02.002_bb0230","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/09273948.2011.645989","article-title":"Interferon alpha 2b in the treatment of uveitic cystoid macular edema","volume":"20","author":"Butler","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0235","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0240","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","article-title":"Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis","volume":"144","author":"Plskova","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.autrev.2013.02.002_bb0245","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon as a treatment for uveitis associated with multiple sclerosis","volume":"89","author":"Becker","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.autrev.2012.10.020","article-title":"Different effects of biological drugs in rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.02.002_bb0255","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.02.002_bb0260","article-title":"Tight control applied to the biological therapy of rheumatoid arthritis","author":"Epis","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2013.02.002_bb0265","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.autrev.2013.02.002_bb0270","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.autrev.2011.07.001","article-title":"Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases","volume":"11","author":"Miserocchi","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2013.02.002_bb0280","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0285","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0290","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.semarthrit.2005.12.003","article-title":"Wegener's granulomatosis: ophthalmic manifestations and management","volume":"35","author":"Pakrou","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2013.02.002_bb0300","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0305","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0310","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0315","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sjogren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.autrev.2013.02.002_bb0320","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/ard.2004.027128","article-title":"Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab","volume":"64","author":"Ahmadi-Simab","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2013.02.002_bb0325","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.2011.08938.x","article-title":"Treatment of primary intraocular lymphoma with rituximab, high dose methotrexate, procarbazine, and vincristine chemotherapy, reduced whole-brain radiotherapy, and local ocular therapy","volume":"157","author":"Taoka","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0330","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2013.02.002_bb0335","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000336188","article-title":"Rituximab for noninfectious uveitis","volume":"51","author":"Miserocchi","year":"2012","journal-title":"Dev Ophthalmol"},{"issue":"11","key":"10.1016\/j.autrev.2013.02.002_bb0340","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2013.02.002_bb0345","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.autrev.2011.02.007","article-title":"Comparison of different IVIg preparations on IL-17 production by human Th17 cells","volume":"10","author":"Maddur","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.02.002_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2013.01.002","article-title":"A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro\/La-related congenital atrioventricular block. A case series and review of the literature","author":"Ruffatti","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.02.002_bb0355","article-title":"The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response","author":"Djoumerska-Alexieva","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2013.02.002_bb0360","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.autrev.2012.04.006","article-title":"Intravenous immunoglobulin for the treatment of Crohn's disease","volume":"12","author":"Rogosnitzky","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0365","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.autrev.2012.08.017","article-title":"Tregitope update: mechanism of action parallels IVIg","volume":"12","author":"Cousens","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0370","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0375","first-page":"23","article-title":"Efficacy of intravenous immunoglobulin in the treatment of Birdshot retinochoroiditis","volume":"25","author":"Cassoux","year":"2002","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.autrev.2013.02.002_bb0380","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1196\/annals.1423.036","article-title":"Human immunoglobulins in intraocular inflammation","volume":"1110","author":"Tellier","year":"2007","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0385","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0002-9394(99)00029-X","article-title":"The treatment of refractory uveitis with intravenous immunoglobulin","volume":"127","author":"Rosenbaum","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.autrev.2013.02.002_bb0390","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","article-title":"Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin","volume":"15","author":"Tselis","year":"2008","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2013.02.002_bb0395","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcjo.2011.12.007","article-title":"Intravenous immunoglobulin (IVIG) for orbital Wegener's granulomatosis","volume":"47","author":"Wiwatwongwana","year":"2012","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"10.1016\/j.autrev.2013.02.002_bb0400","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1468-1331.2011.03627.x","article-title":"Susac syndrome: clinical characteristics and treatment in 29 new cases","volume":"19","author":"Mateen","year":"2012","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2013.02.002_bb0405","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.autrev.2013.02.002_bb0410","doi-asserted-by":"crossref","first-page":"837-44 e1","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.autrev.2013.02.002_bb0415","first-page":"896","article-title":"Longterm visual prognosis of patients with ocular Adamantiades\u2013Behcet's disease treated with interferon-alpha-2a","volume":"35","author":"Krause","year":"2008","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2013.02.002_bb0420","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments","volume":"117","author":"Sobaci","year":"2010","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.autrev.2013.02.002_bb0425","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2013.02.002_bb0430","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T09:15:33Z","timestamp":1562750133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997213000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":86,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1568997213000268"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.02.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}